Add Zee Business as a Preferred Source
Should you buy Biocon shares now? Key takeaways from Q4 FY26 results
Biocon has staged a largely strong performance for the quarter ended March 31, despite an exceptional loss of Rs 80 crore. Are you trading the largecap stock today?
)
Should you trade Biocon shares now? Here's how analysts view its financial performance in Q4.
Written By: ZeeBiz WebTeam
Edited By: Sandeep Singh
Updated: Fri, May 08, 2026
10:02 AM IST
10:02 AM IST
New Delhi, ZeeBiz WebDesk
Bengaluru-headquartered biopharmaceutical firm Biocon has staged an overall strong performance for the final three months of FY26. After market hours on Thursday, the company reported a net profit of Rs 126 crore, marking a year-on-year fall of 63 per cent over the corresponding period a year ago. The company booked an exceptional loss of Rs 80 crore in Q4 of FY26. It had booked an exceptional gain of Rs 20 crore a year ago.
Analysts say the overall overall numbers reflect the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum.
Its revenue for the January-March period grew 2.3 per cent on a year-on-year basis to Rs 4,517 crore.
TRENDING NOW
Although the net profit fell short of analysts' expectations, the company's top line as well as its operational performance met the mark.
According to Zee Business research, Biocon was estimated to report a net profit of Rs 204 crore and revenue of Rs 4,496 crore for the March quarter.
Biocon Q4 operational performance
The Bengaluru-based firm registered March-quarter earnings before interest, taxes, depreciation and amortisation (EBITDA) of Rs 1,020 crore, versus Rs 1078 crore a year ago.
Its margin slipped by 190 basis points, but stayed above the 21 per cent pegged by analysts.
Analysts had estimated the company's EBITDA to be at Rs 941 crore.
Other key takeaways from Q4 FY26 results
Segment revenue
Its core biosimilars business saw 12 per cent growth in revenue, while its generics and CRDMO units saw expansion of 13 per cent and 2 per cent, respectively.
Dividend
Biocon declared a final dividend of Re 0.50 per equity share.
Key approval
During the course of the quarter, the company secured approval the US drug regulator's approval for generic Liraglutide tablets, a medicine used in treating diabetes and weight management indications.
It also launched Denosumab Biosimilars in the US and Canada, adding strength to its overall portfolio.
How to trade Biocon shares now
Before Friday's opening bell on Dalal Street, Zee Business Managing Editor Anil Singhvi highlighted that Biocon futures have support at the Rs 373 mark, citing the company's strong quarterly performance.
He expects a higher level of Rs 397 in the stock.
Earlier in the day, Zee Business's Pooja Tripathi recommended buying the 380 call option in Biocon at Rs 14 for a target of Rs 30 with a stop loss at Rs 6.
However, at the time of publishing this report, the option was already in the money.
ALSO READ: India Inc’s $20.5 billion US bet gathers steam; tech, pharma, manufacturing sectors in focus
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
RELATED NEWS
Biocon Q4 Results Preview: Top line seen rising 2%, margin may slide by 300 bps—What investors can expect
Ajanta Pharma, Biocon shares in focus today after THIS news
Biocon jumps 10% in two days after strong Q2 results; brokerages see up to 18% upside ahead; check price target
Biocon Biologics secures USFDA approval for cancer treatment biosimilar
Union Budget 2025: Healthcare sector gets Rs 98,311 crore; pharma stocks in focus
